Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. ADC Therapeutics SA
  6. News
  7. Summary
    ADCT   CH0499880968

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00:02 2023-02-03 pm EST
4.630 USD   -5.51%
02/02ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
BU
02/01ADC Therapeutics to Participate in February Investor Conferences
BU
01/24Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cami Launch; Maintains Outperform, Speculative Risk Rating

11/09/2022 | 07:31am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ADC THERAPEUTICS SA
02/02ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
BU
02/01ADC Therapeutics to Participate in February Investor Conferences
BU
01/24Morgan Stanley Lowers Price Target on ADC Therapeutics to $5 From $7, Maintains Equalwe..
MT
01/11Transcript : ADC Therapeutics SA Presents at 41st Annual J.P. Morgan Healthca..
CI
01/04IntoCell Announces the Signing of a Material Transfer Agreement with Option to License ..
CI
01/04Global markets live: Microsoft, Nvidia, Cisco, Salesforce, Rivian...
MS
01/04HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $21, Maintains Bu..
MT
01/04ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BU
01/03ADC Therapeutics Names Mohamed Zaki as Chief Medical Officer
MT
01/03ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
BU
More news
Analyst Recommendations on ADC THERAPEUTICS SA
More recommendations
Financials (USD)
Sales 2022 203 M - -
Net income 2022 -150 M - -
Net cash 2022 309 M - -
P/E ratio 2022 -2,41x
Yield 2022 -
Capitalization 370 M 370 M -
EV / Sales 2022 0,30x
EV / Sales 2023 1,34x
Nbr of Employees 312
Free-Float 46,9%
Chart ADC THERAPEUTICS SA
Duration : Period :
ADC Therapeutics SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADC THERAPEUTICS SA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 4,63 $
Average target price 13,14 $
Spread / Average Target 184%
EPS Revisions
Managers and Directors
Ameet Mallik President, Chief Executive Officer & Director
Jose Carmona Chief Financial Officer
Ron Squarer Chairman
Patrick van Berkel Chief Scientific Officer
Michael Mulkerrin Chief Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
ADC THERAPEUTICS SA27.60%392
REGENERON PHARMACEUTICALS, INC.5.06%80 230
VERTEX PHARMACEUTICALS9.87%77 978
WUXI APPTEC CO., LTD.15.80%41 417
BIONTECH SE-3.87%35 092
BEIGENE, LTD.15.96%26 559